Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease. Issue 3 (23rd February 2021)

• Record Type: Journal Article
• Authors: Ebisawa, Kazutoshi; Shimura, Arika; Honda, Akira; Masamoto, Yosuke; Nakahara, Fumio; Kurokawa, Mineo
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 3(2021)
• Page Start: 614
• Page End: 619
• Publication Date: 2021-02-23
• Subjects: Multicentric Castleman's disease -- prednisolone -- tocilizumab; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1834094
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Although anti-interleukin-6 therapy with tocilizumab and siltuximab is recommended for multicentric Castleman's disease (MCD), burdens caused by frequent hospital visits and high drug payments is an issue to be considered. Although glucocorticoid monotherapy might be less effective compared to these agents, substantial proportions of patients can be successfully treated for years. Therefore, we conducted a retrospective analysis of Castleman's disease patients to explore predictors of glucocorticoid responsiveness and revealed that higher hemoglobin and/or lower C-reactive protein levels before starting glucocorticoid monotherapy were associated with lower probability of requirements for second-line treatment among patients initially treated with glucocorticoid. We concluded that glucocorticoids had a potential to induce sustained disease control for indolent MCD patients with specific clinical characteristics.